THE WHAT? Galderma has increased its full-year sales guidance after reporting a 24.6% increase in first-half net sales, driven by strong demand across its dermatology and injectable aesthetics portfolio.
THE DETAILS First-half net sales reached US$3.13 billion, supported by double-digit growth in both the United States and international markets, with all product categories contributing to performance. The Swiss skincare company has raised its full-year sales growth forecast to 19–21%, up from its previous guidance of 17–20%. Galderma said it continues to invest in expanding its manufacturing footprint, with increased production in the US and plans to explore manufacturing capacity in Asia. While the company acknowledged softer consumer sentiment in some markets and ongoing geopolitical and tariff-related uncertainty, it said these factors remain manageable. Galderma also continues to work with the US Food and Drug Administration to address outstanding observations relating to the approval of its botulinum toxin product, Relfydess.
THE WHY? The results demonstrate the resilience of the premium dermatology and injectable aesthetics markets despite macroeconomic uncertainty, while highlighting the strategic importance of diversified manufacturing, regional expansion and innovation pipelines in supporting long-term growth.
Source: Reuters
